imfinzi
astrazeneca ab - durvalumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
abraxane
celgene brasil produtos farmacÊuticos ltda. - paclitaxel - agentes antineoplÁsicos
brecila
accord farmacÊutica ltda - cloridrato de epirrubicina - antibioticos antineoplasicos
collectro
mylan laboratorios ltda - oxaliplatina - antineoplasico
eloxatin
sanofi-aventis farmacÊutica ltda - oxaliplatina - citostaticos alquilantes
farmorubicina
wyeth indÚstria farmacÊutica ltda - cloridrato de epirrubicina - antibioticos antineoplasicos
fauldfluor
libbs farmacÊutica ltda - fluoruracila - antimetabolicos analogos da pirimidina
fluoruracila
accord farmacÊutica ltda - fluoruracila - antineoplasico
fluoruracila
eurofarma laboratÓrios s.a. - fluoruracila - outros antineoplasicos
giotrif
boehringer ingelheim do brasil quÍmica e farmacÊutica ltda. - dimaleato de afatinibe - antineoplasico